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Letter to the Editor
The impact of MYC locus aberrations on outcome of multiple myeloma (MM) patients is still a matter of debate. Aim of this study was to further investigate the influence of them on survival of MM patients treated with high-dose chemotherapy. Our data suggest that the prognostic favorable hyperdiploid MM (HDMM) contains a subgroup with poor survival that is characterized by concomitant MYC translocation and gain of 1q21.
The role of the transcription factor MYC in the pathogenesis of MM has been extensively studied 1 . In contrast, the impact of MYC locus aberrations on outcome of MM patients has been insufficiently investigated and is still a matter of debate. Aim of this study was to further clarify the impact of t(MYC) and MYC locus copy number alterations on outcome of MM patients treated with high-dose chemotherapy and autologous stem cell transplantation (ASCT). Therefore we performed FISH analysis on CD138+ plasma cells of 274 German patients enrolled in the GMMG HD4 study (Please see Supplemental Material for details).
We detected t(MYC) in 62 (23%) samples (Supplemental Table 1 . We found similar trends for t(14;16) and t4;14) (Supplemental Table 1 ) but the sample number in these subgroups in our set were too low to draw any conclusion. In contrast, t(MYC) was not depleted in HDMM in our set but rather showed a higher frequency. One possible explanation for these discrepancies was stated by Affer et al. 4 . Due to high material requirements in case of multiple molecular analyses, samples may be biased for larger tumor mass or aggressive clones. In the HD4 trial processing of MM samples for FISH analyses had priority and we included all patients into our study for whom FISH slides were available.
Nevertheless, we cannot exclude sample bias.
MYC expression data were available for 172 samples (Supplemental Figure 1) 3 . The overexpression is due to active super-enhancers in the translocation partner loci 3, 4 . Samples with concomitant +MYC and t(MYC) showed the highest mean expression level of MYC (11.5, P<0.001) but this result was based on 6 patients only. No significant difference could be detected for three samples with concomitant del(MYC) and t(MYC) (mean: 9.8,
P=0.75).
We analyzed the prognostic impact of MYC aberrations using log-rank tests. could not detect a significant influence of t(MYC) on survival of MM patients enrolled in the IFM99 trials 6 . Neither the UK nor the French trial included the novel drugs bortezomib and lenalidomide.
We and others have recently shown the importance of stratified analyses in MM (n=19), indicating that bortezomib did not overcome the impact of t(MYC).
As the negative impact of t(MYC) was only detectable in HDMM, we focused on this subgroup in an extended analysis. We performed recursive partitioning including t(MYC) and the unfavorable aberrations +1q21 and del(17p13). As this was an exploratory study we used the univariate test type. We identified HDMM with concomitant t(MYC) and +1q21
as poor prognostic group (Supplemental Figure 2) . For PFS +1q21 and t(MYC) had a similar negative impact. The worst PFS was seen in cases with both aberrations ( Figure   3A ). Of note, cases with only one of these aberrations showed no difference in OS compared to cases without these aberrations ( Figure 3B ). In contrast, concomitant t(MYC) and +1q21 had a profound negative impact on OS of HDMM ( Figure 3B ). The findings from the OS analysis suggested a subgroup effect of t(MYC) and +1q21. Interaction analysis using Cox regression on OS showed a significantly different prognostic effect of t(MYC) for patients depending on presence of +1q21 (interaction P=0.048). We performed a multivariate analysis including t(MYC), +1q21, del(17p13), t(4;14) and ISS and identified t(MYC) as independent predictor for PFS (HR = 1.68, P=0.02) but not for OS (HR=1.64, Table 2 ). The non-significant result for OS may be due to the association of t(MYC) with ISS stages II/III or a lack of statistical power.
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Our analysis indicates that the negative impact on outcome of t(MYC) is restricted to
HDMM and is due to an interaction between t(MYC) and +1q21. But was it the functional basis of this impact on survival and why is it apparently limited to HDMM? Linear regression of MYC aberrations on MYC expression levels explained only 12% of the MYC expression variance and several cases without t(MYC) showed high expression levels. In addition, t(MYC) had no significant impact on OS of patients without +1q21, making it unlikely that increased expression of MYC by itself leads to an aggressive phenotype or resistance in HDMM. Recently, Sawyer et al. presented a possible explanation for our findings 9 . They showed that jumping translocations of 1q12 frequently lead to the simultaneous +1q21 and t(MYC), indicating that these aberrations are based on a common mechanism. This may result in further aberrations like del(17p), finally leading to high risk
MM.
An explanation for the apparent limitation of the impact to HDMM may be that NHDMM activates mechanisms or includes aberrations with effects that are equal or even stronger than t(MYC), obscuring the impact of t(MYC). As an example, Walker et al. recently
showed that cases with MAF or MAFB translocations had a tendency to acquire mutations as a consequence of APOBEC deregulation, another potential mechanism leading to highrisk MM 7 .
In conclusion, our data suggest that the prognostic favorable HDMM contains a subgroup with poor survival that is characterized by the presence of t(MYC) and +1q21. This study shows the importance of stratified analyses in a heterogeneous cancer like MM for the detection and investigation of further biomarkers of outcome.
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Cytogenetic analyses
Interphase fluorescence in situ hybridization was performed as previously described 1 . A three-color MYC (8q24) break-apart probe (Kreatech, Amsterdam, Netherlands) was used to detect MYC aberrations. Ploidy was assessed using gains of at least two of the chromosomes 5, 9, 11, 15 and 19. A 5-chromosome combination has a sensitivity of ~90% and a specificity >90% for identification of hyperdiploid MM 2 . Subclones were defined as aberrations found in less than 60% of analyzed cells, if at least one aberration was detected in more than 80% of cells 3 .
Gene expression analyses
For gene expression analysis we used the HD4 data set deposited in ArrayExpress (accession number E-MTAB-2299) collected using U133 Version 2.0 plus arrays (Affymetrix). As chip definition file (CDF) we used the Affymetrix U133 Version 2.0 plus array CDF (v17) mapping to Entrez genes 4 . Expression data were normalized using GC-RMA. Two known batch effects were corrected using Combat 5 .
Statistical analysis
Fisher's exact test was used to compare the distribution of MYC abnormalities between cohorts. Group comparison of expression data was done using the Mann-Whitney
Wilcoxon test. PFS and OS were calculated from the time of start of treatment and the survival rates were estimated using the method of Kaplan and Meier. The log-rank test and the Cox proportional hazards model were used to perform group comparisons and assess the impact of prognostic factors, respectively. The Bonferroni-Holm method was used if results were corrected for multiple testing. Prognostic subgroups were identified using recursive partitioning as implemented in the R package party 6 . Briefly, subgroups of patients with significantly distinct prognosis are identified based on their association with selected clinico-pathological parameters. A hierarchical tree is built top-down starting with all patients. The first split is based on the parameter with the strongest association with survival. Subgroups are split until no further significant association between survival and any parameter is found or subgroups become too small. The statistical analyses were carried out using the R software package 3.1.1.
